N
NovaDigm Therapeutics
Develops vaccines that protect patients from contracting fungal and bacterial infections
About NovaDigm Therapeutics
NovaDigm Therapeutics is a biotechnology company focused on developing innovative immunotherapeutics and preventative vaccines to combat fungal and bacterial diseases. These diseases can be recurrent, drug-resistant, and potentially life-threatening. The company's lead development candidate, NDV-3A, is the first vaccine to show preclinical efficacy in reducing the severity of diseases caused by both fungal and bacterial pathogens. NDV-3A is currently in Phase 2 clinical development for treating recurrent vulvovaginal candidiasis (RVVC), with plans for additional indications in the future.
NovaDigm serves patients who suffer from recurrent and drug-resistant infections, primarily targeting the healthcare market. The company's business model revolves around the research, development, and eventual commercialization of its vaccine candidates. Revenue is expected to be generated through the successful approval and sale of these vaccines, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jun 2017 | $6M | — | US Department of War | — |
| SERIES BOther financing | Nov 2014 | $7M | $28M | RMI Partners | — |
Growth signals
Latest recorded traffic for NovaDigm Therapeutics is 2.3K monthly website visits, up 21.1% over the last three months. NovaDigm Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NovaDigm Therapeutics in the Grand Forks ecosystem
The NovaDigm Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of War
Series A2 investors entered at this stage
Domain Associates
RMI Partners
Other known investors1 additional known investor
UMass Lowell
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NovaDigm Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NovaDigm Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









